Johnson Taylor A, Singla Dinender K
Division of Metabolic and Cardiovascular Sciences, Burnett School of Biomedical Sciences, University of Central Florida, 4110 Libra Dr., Orlando, FL, USA.
Methods Mol Biol. 2017;1553:249-264. doi: 10.1007/978-1-4939-6756-8_20.
Cell therapies have been explored as a potential treatment avenue to treat heart diseases, such as myocardial infarction, doxorubicin-induced cardiomyopathy, and heart failure. Embryonic and adult stem cells (ASCs) have been examined in animal and clinical settings. Unlike embryonic and induced pluripotent stem cells, ASCs do not pose a threat to form teratomas, nor do they have immune system concerns, making them ideal for therapeutic use in humans. In this review, we will investigate different characteristics and sources of adult stem cells and progenitor cells, as well as determine their efficacy in cell transplantation in experimental and clinical trials. In addition, we will propose other research avenues that may promote further understanding and use of ASCs in therapeutic designs.
细胞疗法已被探索作为治疗心脏病的一种潜在治疗途径，如心肌梗死、阿霉素诱导的心肌病和心力衰竭。胚胎干细胞和成体干细胞已在动物和临床环境中进行了研究。与胚胎干细胞和诱导多能干细胞不同，成体干细胞不会形成畸胎瘤，也不存在免疫系统问题，使其成为人类治疗应用的理想选择。在本综述中，我们将研究成体干细胞和祖细胞的不同特征和来源，并确定它们在实验和临床试验中细胞移植的疗效。此外，我们将提出其他研究途径，以促进对成体干细胞在治疗设计中的进一步理解和应用。
